0.735

2.37% +0.017

After Hours: .735

Alzamend Neuro Inc (ALZN)

Overview News Price History Financials Why ALZN Down? Discussions Forecast Stock Split

Alzamend Neuro Inc stock is currently priced at $0.735, with a 24-hour trading volume of 25,266. It has seen a +2.37% increased in the last 24 hours and a -19.14% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.7293 pivot point. If it approaches the $0.7587 resistance level, significant changes may occur.

Previous Close:

$0.718

Open:

$0.74

24h Volume:

25,266

Market Cap:

$4.81M

Revenue:

Net Income/Loss:

$-12.40M

P/E Ratio:

-4.5938

EPS:

-0.16

Net Cash Flow:

$-9.08M

1W Performance:

+5.00%

1M Performance:

-19.14%

6M Performance:

-55.45%

1Y Performance:

+44.12%

1D Range:

$0.70

$0.74

52W Range:

$0.1132

$2.032

Alzamend Neuro Inc Stock (ALZN) Company Profile

Name

Alzamend Neuro Inc

Sector

Healthcare (1190)

Industry

Biotechnology (685)

Phone

844 722 6333

Address

3500 Lenox Road NE, Suite 1500, Atlanta

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ALZN's Discussions on Twitter

Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy

Alzamend Neuro Inc Stock (ALZN) Latest News

Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Why Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Benzinga

Why ReNew Energy Global Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Alzamend Neuro Inc Stock (ALZN) Financials Data

Alzamend Neuro Inc (ALZN) Net Income 2024

ALZN net income (TTM) was -$12.40 million for the quarter ending January 31, 2024, a +19.69% increase year-over-year.

Alzamend Neuro Inc (ALZN) Cash Flow 2024

ALZN recorded a free cash flow (TTM) of -$9.08 million for the quarter ending January 31, 2024, a -10.04% decrease year-over-year.

Alzamend Neuro Inc (ALZN) Earnings per Share 2024

ALZN earnings per share (TTM) was -$1.89 for the quarter ending January 31, 2024, a +24.70% growth year-over-year.

Alzamend Neuro Inc Stock (ALZN) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
AULT MILTON C III	Director	Apr 01 '24	Buy	0.91	334	304	770,699
AULT MILTON C III	Director	Jan 05 '24	Buy	1.02	5,000	5,092	768,365
AULT MILTON C III	Director	Jan 05 '24	Buy	1.06	2,000	2,127	770,365
AULT MILTON C III	10% Owner	Dec 26 '23	Buy	0.90	500	450	26,032
AULT MILTON C III	10% Owner	Dec 22 '23	Buy	0.92	200	185	166,866
Katzoff David J	Chief Financial Officer	Sep 26 '23	Buy	0.19	53,000	10,234	81,000
AULT MILTON C III	10% Owner	May 24 '23	Buy	0.59	18,000	10,705	383,000

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.